Immunovant Quarterly Cash Flow Statement
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
30.47+0.21 (+0.69%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunovant free cash flow
In the quarter ended Jun 30, 2026, Immunovant generated -$124.4 million of operating cash flow. That left free cash flow of -$124.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
Immunovant cash flow statement (quarterly)
| Quarter (USD) | Q1 20272026-06-30 | Q4 20262026-03-31 | Q3 20262025-12-31 | Q2 20262025-09-30 | Q1 20262025-06-30 | Q4 20252025-03-31 | Q3 20252024-12-31 | Q2 20252024-09-30 | Q1 20252024-06-30 | Q4 20242024-03-31 | Q3 20242023-12-31 | Q2 20242023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -153.22M | -147.86M | -110.64M | -126.50M | -120.61M | -106.45M | -111.12M | -109.12M | -87.15M | -75.32M | -51.42M | -58.66M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 92.00K | 96.00K | 101.00K | 105.00K | 107.00K | 109.00K | 99.00K | 89.00K | 80.00K | 64.00K | 58.00K | 56.00K |
| Stock-Based Compensation | 13.77M | 11.14M | 12.71M | 13.36M | 18.51M | 11.69M | 11.65M | 12.69M | 13.46M | 9.68M | 10.22M | 10.53M |
| Change in Working Capital | 3.03M | -786.00K | 1.88M | -1.09M | -9.27M | -572.00K | 3.69M | 20.45M | -732.00K | 14.71M | -8.78M | -10.95M |
| Operating Cash Flow | -124.41M | -95.06M | -92.33M | -102.52M | -117.41M | -110.64M | -100.39M | -88.65M | -76.20M | -59.70M | -47.10M | -60.06M |
| Capital Expenditures | — | -8.00K | 0 | 0 | 0 | -201.00K | -180.00K | -196.00K | -182.00K | -150.00K | -131.00K | -34.00K |
| Investing Cash Flow | — | -8.00K | 0 | 0 | 0 | -201.00K | -180.00K | -196.00K | -182.00K | -150.00K | -131.00K | -34.00K |
| Financing Cash Flow | 20.10M | 3.64M | 564.60M | 24.59M | 2.92M | 450.61M | 2.46M | 730.00K | 686.00K | 1.54M | 469.84M | 148.00K |
| Net Change in Cash | -104.31M | -92.42M | 472.65M | -77.04M | -115.06M | 339.29M | -98.26M | -87.06M | -75.36M | -55.57M | 421.01M | -60.03M |
| Free Cash Flow | -124.41M | -95.07M | -92.33M | -102.52M | -117.41M | -110.84M | -100.57M | -88.84M | -76.38M | -59.85M | -47.23M | -60.09M |
This table shows 12 quarterly periods of Immunovant's cash flow statement, from Q1 2027 back to Q2 2024, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IMVT's reporting calendar. What is a cash flow statement?